PRESS-RELEASE ·Filed Oct 5, 2026
Press release · Leadership
Actionable Insight • Neutral
Routine leadership appointments with no immediate financial catalyst — monitor for future strategic updates or commercial milestones related to the NULISA platform.
Latest settled — T+5d
ALMR ▼ -27.09% at T+5d
NEUTRAL call -27.09% · α vs SPY -26.95% · entry $32.26 → $23.52
Latest observation: T+13 -8.40% FF3 residual α
T+1d
-13.92%
call -13.92% · α -13.68%
$27.77
settled 21d ago
T+5d
-27.09%
call -27.09% · α -26.95%
$23.52
settled 15d ago
T+20d
Pending
in 6d
T+60d
Pending
in 2mo
Price Chart
Loading chart...
Executive Summary
Alamar Biosciences announced the appointment of Bob Ragusa (former CEO of GRAIL and COO of Illumina) to its board of directors, along with two leadership additions: John Brottem as general counsel and Amelia Merrill as chief people officer. The appointments are routine organizational changes with no material financial impact disclosed.
Key Facts
- Bob Ragusa appointed to board of directors; former CEO of GRAIL and COO of Illumina
- John Brottem appointed as general counsel; former GC of Outset Medical
- Amelia Merrill appointed as chief people officer; former SVP People at Guardant Health
- No financial terms, compensation, or material agreements disclosed
Financial Impact
No financial impact stated
Risk Factors
- No financial data or guidance provided to assess impact
- Forward-looking statements subject to competitive and regulatory risks
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3374993 |
24 reports for ALMR
100% Hit rate @ T+60 Went positive at some point 12 of 13 best @ T+60▲ +34.17%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 12d ago | 144 | $27.42 | awaiting T+60 | — | $30.69 (−11.93%) |
Oct 14, 2026 12d ago | 144 | $27.42 | awaiting T+60 | — | $30.69 (−11.93%) |
Oct 14, 2026 12d ago | 144 | $27.42 | awaiting T+60 | — | $30.69 (+11.93%) |
Oct 5, 2026 21d ago | Press Release | $32.26 | awaiting T+60 | — | $30.69 (−4.87%) |
Sep 24, 2026 4w ago | Press Release | $32.80 | awaiting T+60 | — | $30.69 (−6.43%) |
Sep 1, 2026 7w ago | 8-K | $30.49 | awaiting T+60 | — | $30.69 (+0.66%) |
Aug 10, 2026 11w ago | 8-K | $36.57 | awaiting T+60 | — | $30.69 (−16.08%) |
Jul 13, 2026 15w ago | Press Release | $27.40 $32.26 | ▲ +17.74% | ▲ +13.74% | $30.69 (+12.01%) |
Jul 10, 2026 15w ago | Press Release | $28.42 $38.13 | ▲ +34.17% | ▲ +31.53% | $30.69 (+7.99%) |
May 8, 2026 24w ago | 8-K | $23.96 $27.11 | ▲ +13.15% | ▲ +8.31% | $30.69 (+28.09%) |
Showing 10 of 24
US Market Status
Market Closed — Opens Wed (12h 40m)
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers